Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.

An update on FVII gene therapy and more.

Updates on Daklinza, Technivie, and the ACE910 trial

There are times when less really is more. With the June 6, 2014, US Food and Drug Administration (FDA) approval...

Progress. For years, the bleeding disorders community has been waiting for meaningful progress for a greater understanding of hemophilia, for...

A six-year study by the US Centers for Disease Control and Prevention (CDC) of patients with inhibitors, antibodies to infused...

Update, November 2014: The St. Jude/UCL gene therapy trial now has data from all 10 participants, to be published in...

Five pilot sites have been approved and first patients enrolled

During the past 20 years, advances in hemophilia treatment, including recombinant factor therapy, have allowed people with hemophilia to take...

Update, August 2013: The FDA approved Tivicay® (dolutegravir), manufactured by ViiV Healthcare, a GlaxoSmithKline company. Tivicay is an integrase strand...

For Christine Orr, the trigger for starting prophylaxis wasn’t just one thing. It was everything. Orr’s son, John, diagnosed with...

Update, October 22, 2015: The US Food and Drug Administration (FDA) issued a warning that AbbVie’s Viekira Pak ® and...